TKS 1 made an investment in gastrointestinal-focused clinical research company Objective GI.
What you should know:
1. The investment will grow Objective GI’s network of GI-specialty clinical research sites in the U.S.
2. TKS 1 is a joint venture between SPRIM and Tikehau Capital. They provide healthcare-focused companies with early-stage funding. SPRIM Ventures Partner Laurent Benissan said, "This investment means Objective GI can leverage the resources and expertise of SPRIM. … We’re excited to offer the funding and look forward to accelerated growth to the Objective GI infrastructure and network."
3. Objective GI currently has 60 physician partners at five U.S.-based sites. The company projects to add 30 more sites by the end of 2021.
4. Objective GI CEO Colleen Hoke said, "This investment marks a major step forward for our company to leverage our research platform and strengthen our core offerings. We are focused on providing the most advanced research structure to enable leading partnered physician groups to enhance the quality and value of patient care through clinical research."